Welcome to our dedicated page for INSULET SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INSULET's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INSULET's regulatory disclosures and financial reporting.
INSULET CORP director Timothy J. Scannell received an annual equity award in the form of restricted stock units. The grant covers 1,660 shares of common stock, awarded at no cash cost and recorded as an acquisition of common stock.
The RSUs will be settled in shares of common stock on a one-for-one basis and vest in full on April 30, 2027. After this award, Scannell directly holds 33,024 shares of Insulet common stock, showing this is a routine, compensation-related equity grant rather than an open-market purchase or sale.
MINOGUE MICHAEL R reported acquisition or exercise transactions in this Form 4 filing.
INSULET CORP director Michael R. Minogue reported an equity grant and updated share holdings. He received an annual equity award of 1,660 restricted stock units (RSUs), which will be settled one-for-one in common shares and vest in full on April 30, 2027. Following the grant, he holds 2,438 common shares directly and 17,483 common shares indirectly through a trust.
Huffines Robert Luther reported acquisition or exercise transactions in this Form 4 filing.
Insulet Corp director Robert Luther Huffines received an annual equity award of 1,660 shares of common stock in the form of restricted stock units at no cash cost. These RSUs vest in full on April 30, 2027 and will be settled one-for-one in shares after his board service ends, according to his deferral election. Following this grant, he beneficially owns 2,298 common shares directly.
Hopfield Jessica reported acquisition or exercise transactions in this Form 4 filing.
Insulet Corp director Jessica Hopfield received an equity award of 1,660 restricted stock units (RSUs) of common stock. The award was granted at no cash cost to her as part of annual equity compensation. These RSUs will vest in full on April 30, 2027 and settle one-for-one in Insulet common shares. After this grant, she directly holds 29,355 shares of Insulet common stock, highlighting that the transaction reflects compensation rather than an open-market purchase or sale.
Frederick Wayne A.I. reported acquisition or exercise transactions in this Form 4 filing.
INSULET CORP director Frederick Wayne A.I. received an equity grant of 1,660 shares of common stock on a grant/award basis, with no cash paid per share. These are restricted stock units that vest in full on April 30, 2027. After the award, he holds 3,818 shares directly. Settlement of the vested RSUs is deferred under Insulet’s non-employee director deferred compensation plan until after his board service ends.
BORIO LUCIANA reported acquisition or exercise transactions in this Form 4 filing.
INSULET CORP director Luciana Borio received an equity grant of 1,660 shares of common stock in the form of restricted stock units. The RSUs are an annual equity award that will be settled on a one-for-one basis in common stock. They vest in full on April 30, 2027, aligning her compensation with long-term shareholder interests. Following this award, she holds a total of 4,747 shares of Insulet common stock directly.
Insulet Corporation reported governance updates and voting results from its 2026 annual stockholder meeting. The Board approved amended and restated Bylaws that designate the Delaware Court of Chancery, or other Delaware courts as needed, as the exclusive forum for certain corporate disputes, and federal district courts as the exclusive forum for claims under the U.S. Securities Act of 1933.
At the meeting, 61,782,973 of 69,263,714 shares entitled to vote were represented, forming an 89.19% quorum. Stockholders elected three Class I directors for three-year terms, approved the advisory vote on executive compensation, and ratified PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026.
Insulet Corp President and CEO Ashley McEvoy reported a routine tax-related share disposition and updated holdings. A total of 1,411 shares of common stock were withheld on May 13, 2026 at $148.84 per share to cover tax obligations tied to vesting restricted stock units, according to the footnote. After this withholding, McEvoy directly owns 22,551 common shares and indirectly holds 4 additional shares through a trust.
Insulet Corp. passive investor Capital Research Global Investors amended its Schedule 13G to report beneficial ownership of 1,669,556 shares of Common Stock, equal to 2.4% of 70,395,848 shares outstanding as of 03/31/2026. The filing shows sole voting power of 1,664,274 and sole dispositive power of 1,669,556.
Insulet Corporation reported strong Q1 2026 results, with revenue of $761.7 million, up 33.9% from a year earlier, driven by 36.9% growth in Omnipod products and especially rapid international expansion.
Net income rose to $91.1 million and diluted EPS to $1.30, helped by higher volumes and pricing, partly offset by a lower gross margin of 69.5% due to increased inventory reserves and warranty costs from a voluntary Omnipod 5 medical device correction.
Operating cash flow was $113.8 million and free cash flow $89.5 million. Insulet ended the quarter with $480.4 million in cash and $948.1 million of net debt, and repurchased $300 million of stock under accelerated share repurchase agreements while extending and expanding its buyback authorization.